P&N Blog

Prostate cancer is the second most common cancer diagnosed in men worldwide and one of the most survivable when it's caught early (Raychaudhuri et al., JAMA, 2025). Most men diagnosed today have no symptoms — the cancer is found only because of an abnormal screening test. Whether and when to screen, how to interpret a PSA result, and which treatment to pursue are all decisions that should be made with your doctor, not handed down by one. Understanding each step protects your health — and helps you recognize when something in your care has gone wrong.

Perantinides & Nolan has recovered 75+ verdicts and settlements over $1 million for patients across Akron and Northeast Ohio over 55+ years. If a delayed diagnosis or missed follow-up may have harmed you or a loved one, call 330-253-5454 for a free, confidential consultation.

What is prostate cancer?

The prostate is a small gland below the bladder that produces fluid found in semen. Prostate cancer occurs when prostate cells grow abnormally. It is not one disease — some prostate cancers grow slowly and never cause symptoms, while others are aggressive and can spread to lymph nodes, bones, and other organs (Fonteyne et al., The Lancet, 2026). This range is why treatment is never one-size-fits-all.

When should men start screening?

Most guidelines suggest beginning the screening conversation between ages 45 and 55 for men at average risk:

• Average risk: The American Urological Association suggests offering a baseline PSA test around ages 45–50 (Wei et al., AUA/SUO Guideline, 2023). The USPSTF recommends men 55–69 make an individual decision with their doctor, and generally advises against routine screening after 70, when harms tend to outweigh benefits (US Preventive Services Task Force, JAMA, 2018).
• Family history: A father or brother with prostate cancer roughly doubles a man's risk, and inherited mutations such as BRCA1, BRCA2, and Lynch syndrome raise it further (Attard et al., The Lancet, 2016; NCCN Guidelines, Prostate Cancer Early Detection, 2026). Men with a strong family history are often advised to start the conversation around age 40–45.
• Race: Black men have a substantially higher incidence of prostate cancer, are diagnosed younger, and face a two- to threefold higher risk of dying from it than white men — disparities driven largely by unequal access to care and treatment, not biology (Xu et al., American Family Physician, 2024). Many experts recommend Black men begin the screening conversation around age 40.

These age ranges are guidance, not hard rules — the standard of care requires shared decision-making about when to start or stop screening, not a specific start or stop age.

What does the PSA test measure, and what counts as abnormal?

The PSA (prostate-specific antigen) blood test measures a protein made by the prostate. A PSA above roughly 3 ng/mL is commonly cited as the threshold prompting further evaluation, though what counts as "elevated" varies with age, and levels can rise for benign reasons like an enlarged prostate or infection (Fonteyne et al., The Lancet, 2026). Because a single elevated result isn't conclusive, it's typically repeated and interpreted alongside other factors — not acted on immediately. A digital rectal exam (DRE) is sometimes done alongside PSA but should not be used alone as a screening test (NCCN Guidelines, Prostate Cancer Early Detection, 2026).

Risk calculators (such as the PCPT, ERSPC, and PBCG calculators) combine PSA, age, race, family history, and other factors into a single risk estimate, most often used to help decide whether to proceed to biopsy. They're a useful starting point for a conversation with your doctor — but their accuracy is only moderate (around 0.72–0.74 out of 1.0 in USPSTF's evidence review), they reflect population averages rather than individual certainty, and several were built mainly on data from men of European ancestry, making them less reliable for Black men and other groups (US Preventive Services Task Force, JAMA, 2018). A calculator result should never be the sole basis for deciding you don't need further testing.

What happens after an abnormal PSA?

MRI. When PSA is elevated, a multiparametric MRI (mpMRI) is now a recommended step before biopsy. MRI-guided evaluation detects roughly twice as many clinically significant cancers as older approaches, reduces unnecessary detection of harmless cancers, and lets some men safely avoid a biopsy altogether (Drost et al., European Urology, 2020; Sandhu et al., The Lancet, 2021). A negative MRI does not fully rule out cancer.

Biopsy. A biopsy is the only way to confirm cancer. Modern biopsies are increasingly MRI-guided ("targeted biopsy"), improving detection of higher-risk disease (NCCN Guidelines, Prostate Cancer Early Detection, 2026). The biopsy result — reported as a Grade Group or Gleason score — together with PSA and stage, determines how aggressive the cancer is and drives every treatment decision that follows. Ask for these numbers directly; understanding them lets you participate meaningfully in your own care.

What are the treatment options after a diagnosis?

There is rarely one "correct" treatment. The right choice depends on risk level, age, health, life expectancy, and personal values about side effects.

• Active surveillance is the preferred approach for many men with low-risk disease. Rather than treating immediately, doctors monitor closely with PSA tests, periodic MRI, and repeat biopsies, moving to treatment only if the cancer progresses. The landmark ProtecT trial found that active monitoring produced 15-year survival outcomes similar to immediate surgery or radiation for many men, while avoiding or delaying side effects (Hamdy et al., New England Journal of Medicine, 2023).
• Surgery (radical prostatectomy) removes the entire prostate and is a well-established curative option for localized cancer, particularly in younger, healthier men. It carries risks including long-term urinary incontinence and erectile dysfunction, which your surgeon should walk through in detail based on your specific case before you decide.
• Radiation therapy — external beam or implanted seeds (brachytherapy) — is often equivalent to surgery for localized disease and may be combined with hormone therapy for higher-risk cancers.
• Hormone therapy (androgen deprivation therapy) lowers androgens that fuel prostate cancer growth and is a mainstay for advanced disease, often combined with radiation for higher-risk localized cancer.
• Chemotherapy is generally reserved for advanced or metastatic disease.
• Clinical trials are worth discussing at every stage, not just as a last resort — especially for advanced disease or cancers with specific genetic features.

Frequently Asked Questions

What PSA level is considered abnormal?
A PSA above roughly 3 ng/mL commonly prompts further evaluation, though the threshold varies by age and should be interpreted by a doctor alongside other risk factors — not acted on from a single result alone.

Do all men need a prostate biopsy after an abnormal PSA?
No. Current guidelines recommend an MRI before biopsy in most cases; a low-risk MRI result combined with a low risk-calculator score may allow a man to safely delay or avoid biopsy after discussing it with his doctor.

Is active surveillance the same as doing nothing?
No. Active surveillance is a structured monitoring plan with regular PSA tests, imaging, and biopsies, with treatment starting promptly if the cancer shows signs of progressing.

Could a delayed prostate cancer diagnosis be medical malpractice in Ohio?
It can be, if a doctor failed to order appropriate follow-up on a rising PSA, delayed a necessary biopsy, or didn't discuss your options for screening or treatment, and that delay allowed the cancer to progress. Learn more on our Late Cancer Diagnosis page, or call 330-253-5454 for a free, confidential case review.

Why understanding your own care matters

You can protect yourself by asking for your specific numbers (PSA, Grade Group/Gleason score, risk category), asking why a test or treatment is recommended and what the alternatives are, requesting a second opinion when the path forward is unclear, and following up on every abnormal result. When patients are informed partners in their care, mistakes are less likely to slip through unnoticed.

If you believe a delay or error in a prostate cancer diagnosis or treatment may have harmed you or a loved one, call 330-253-5454 for a free, confidential consultation with Perantinides & Nolan.

This article is for general educational purposes only and is not medical or legal advice. If you have questions about your health, speak with a qualified physician. Attorney Advertising. Prior results do not guarantee a similar outcome.

Perantinides & Nolan Co., L.P.A. is proud to announce that three of our attorneys — Paul G. Perantinides, Chris T. Nolan, and Antonios P. Tsarouhas — have been selected for inclusion in the 2027 Edition of The Best Lawyers in America®, one of the oldest and most respected peer-review publications in the legal profession.

For over fifty years, the Akron law firm of Perantinides & Nolan has fought for the rights of the injured across Northeast Ohio. However, our dedication to justice extends far beyond the walls of the courtroom. Recently, our founding partner, Paul Perantinides, was featured by Community Legal Aid to discuss the crucial role that legal professionals play in supporting access to justice for the most vulnerable members of our community.

FOR IMMEDIATE RELEASE - Akron Bar Association Perantinides & Nolan Leadership Academy Launches Countywide Law Firm Food Drive Competition

AKRON, OHIO — At Perantinides & Nolan, our dedication to the Northeast Ohio community extends far beyond the courtroom. We believe in standing up for those who need it most. That is why we are privileged and honored to announce a $125,000 matching gift to Pano’s Kick Childhood Cancer Fund at Akron Children’s Hospital.

At Perantinides & Nolan, Co., L.P.A., we have spent over 50 years representing Ohio families in catastrophic trucking accidents and wrongful death claims. Recently, we resolved a tragic case that serves as a critical warning to anyone who drives a company vehicle for work.

We're proud to foster the Next Generation of Legal Excellence through The Perantinides & Nolan Leadership Academy presented by the Akron Bar Association.

Perantinides & Nolan Co., L.P.A. is pleased to announce that partners Paul Perantinides, Chris Nolan, and Tony Tsarouhas have been selected to the 2026 Super Lawyers list. 

P&N is proud to have 3 lawyers listed in the 2026 editions of The Best Lawyers in America® P&N has also been named a Tier 1 firm in Akron for Personal Injury Litigation - Plaintiffs by U.S. News – Best Lawyers®.

We're pleased to again be the presenting sponsor of the Andrea Rose Teodosio Foundation Angel ART Auction.

P&N is pleased to announce that 3 of our attorneys were selected to the Ohio Super Lawyers® List for 2025.

We are pleased to announce that Perantinides & Nolan Co., L.P.A. has been recognized by Best Law Firms regionally for Personal Injury Litigation.

We are pleased to announce that 2 of our lawyers have been included in the 2025 edition of The Best Lawyers in America^®. 

As a first-year law student in 1967, Paul Perantinides was walking on South Main Street in downtown Akron, looking up at the windows of the buildings, when a distinguished-looking man approached him and said, “Excuse me, young man, are you lost?”

Olivia was born with cerebral palsy, resulting from negligent medical care in her delivery. Now she is working as a summer intern at P&N as she prepares for a career in helping children with disabilities. 

We are pleased to share on behalf of the Campbell Memorial Alumni Association there has been a new scholarship established by Attorney Paul Perantinides.

P&N is proud to be the Presenting Sponsor of the Annual Andrea Rose Teodosio Foundation’s 2024  Angel ART Auction.

Please join us in congratulating our Attorneys who have been Awarded with the prestigious AV Preeminent and Client Champion Awards!

Please join us in congratulating our Attorneys who have been selected as 2024 Super Lawyers!

Congratulations to Casey Ruppen, P&N Law Clerk and member of The University of Akron School of Law Mock Trial Team who recently won 2023 National Civil Trial Competition!